Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet..

J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.

2.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
3.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

Tefferi A, Barbui T.

Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):849.

4.

Chronic myeloproliferative disorders.

Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, Marchetti M.

Hematology Am Soc Hematol Educ Program. 2003:200-24. Review.

PMID:
14633783
5.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
6.

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.

Tefferi A, Barbui T.

Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.

PMID:
27991718
7.

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.

Tefferi A.

Am J Hematol. 2012 Mar;87(3):285-93. doi: 10.1002/ajh.23135. Review.

8.

Myeloproliferative Neoplasms: A Contemporary Review.

Tefferi A, Pardanani A.

JAMA Oncol. 2015 Apr;1(1):97-105. doi: 10.1001/jamaoncol.2015.89. Review.

PMID:
26182311
9.

Current treatment concepts of Philadelphia-negative MPN.

Wolf D, Rudzki J, Gastl G.

Curr Cancer Drug Targets. 2011 Jan;11(1):44-55. Review.

PMID:
21062242
10.

Front-line therapy in polycythemia vera and essential thrombocythemia.

Barbui T, Finazzi MC, Finazzi G.

Blood Rev. 2012 Sep;26(5):205-11. doi: 10.1016/j.blre.2012.06.002. Epub 2012 Jul 10. Review.

PMID:
22784966
11.
12.

[The chronic Philadelphia chromosome-negative myeloproliferative syndrome II. Clinical findings, diagnostics and treatment].

Hasselbalch HC, Mourits-Andersen HT, Jensen BA, Jensen MK, Nielsen OJ.

Ugeskr Laeger. 2001 Apr 30;163(18):2474-7. Review. Danish.

PMID:
11379260
13.
14.

Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.

Tefferi A, Barbui T.

Mayo Clin Proc. 2015 Sep;90(9):1283-93. doi: 10.1016/j.mayocp.2015.05.014. Review.

PMID:
26355403
16.

Therapeutic options for essential thrombocythemia and polycythemia vera.

Solberg LA Jr.

Semin Oncol. 2002 Jun;29(3 Suppl 10):10-5. Review.

PMID:
12096352
17.

Contemporary approach to essential thrombocythemia and polycythemia vera.

Aruch D, Mascarenhas J.

Curr Opin Hematol. 2016 Mar;23(2):150-60. doi: 10.1097/MOH.0000000000000216. Review.

PMID:
26717193
18.

Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.

Tefferi A.

Leuk Lymphoma. 2010 Apr;51(4):576-82. doi: 10.3109/10428191003605313. Review.

PMID:
20214447
19.

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Tefferi A, Vainchenker W.

J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10. Review.

PMID:
21220604
20.

Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ.

Curr Drug Targets. 2011 Mar 1;12(3):392-419. Review.

PMID:
21143149

Supplemental Content

Support Center